Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H17N2O |
Molecular Weight | 277.3404 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 1 |
SHOW SMILES / InChI
SMILES
CC1=C2C=C[N+](C)=CC2=C(C)C3=C1NC4=C3C=C(O)C=C4
InChI
InChIKey=YZQRAQOSAPWELU-UHFFFAOYSA-O
InChI=1S/C18H16N2O/c1-10-15-9-20(3)7-6-13(15)11(2)18-17(10)14-8-12(21)4-5-16(14)19-18/h4-9,21H,1-3H3/p+1
Molecular Formula | C18H16N2O |
Molecular Weight | 276.3324 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/7003658
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7003658
Elliptinium is an antineoplastic agent, which was used in the treatment of metastatic breast cancer in France under the name Celiptium. The drug is known to intercalate into DNA and inhibit topoisomerase II. Several studies have demonstrated that this molecule can be oxidized, yielding a reactive electrophilic form, which is able to bind covalently to a nucleophilic biological molecule.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7003658 |
|||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CELIPTIUM Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Anti-cryptosporidial drug activity screened with an immunosuppressed rat model. | 1991 Nov-Dec |
|
Viral and immunologic follow up of 4 to 9 years of AIDS treatments by quadruple combinations of virostatics including integrase inhibitors applied in short sequences differing by drug rotation. | 2002 Jan |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8484977
In a clinical study, elliptinium (acetate salt) was given at a dose of 80 mg/m2 daily for 3 consecutive days every 21 days.
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:02:36 GMT 2023
by
admin
on
Fri Dec 15 16:02:36 GMT 2023
|
Record UNII |
1F1959S062
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C582
Created by
admin on Fri Dec 15 16:02:36 GMT 2023 , Edited by admin on Fri Dec 15 16:02:36 GMT 2023
|
||
|
NCI_THESAURUS |
C1968
Created by
admin on Fri Dec 15 16:02:36 GMT 2023 , Edited by admin on Fri Dec 15 16:02:36 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000087741
Created by
admin on Fri Dec 15 16:02:36 GMT 2023 , Edited by admin on Fri Dec 15 16:02:36 GMT 2023
|
PRIMARY | |||
|
996
Created by
admin on Fri Dec 15 16:02:36 GMT 2023 , Edited by admin on Fri Dec 15 16:02:36 GMT 2023
|
PRIMARY | |||
|
C90495
Created by
admin on Fri Dec 15 16:02:36 GMT 2023 , Edited by admin on Fri Dec 15 16:02:36 GMT 2023
|
PRIMARY | |||
|
C027767
Created by
admin on Fri Dec 15 16:02:36 GMT 2023 , Edited by admin on Fri Dec 15 16:02:36 GMT 2023
|
PRIMARY | |||
|
SUB01869MIG
Created by
admin on Fri Dec 15 16:02:36 GMT 2023 , Edited by admin on Fri Dec 15 16:02:36 GMT 2023
|
PRIMARY | |||
|
1F1959S062
Created by
admin on Fri Dec 15 16:02:36 GMT 2023 , Edited by admin on Fri Dec 15 16:02:36 GMT 2023
|
PRIMARY | |||
|
42723
Created by
admin on Fri Dec 15 16:02:36 GMT 2023 , Edited by admin on Fri Dec 15 16:02:36 GMT 2023
|
PRIMARY | |||
|
58337-34-1
Created by
admin on Fri Dec 15 16:02:36 GMT 2023 , Edited by admin on Fri Dec 15 16:02:36 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|